Friday, August 28
Bankruptcy, buyouts, and a blockbuster drug approval
A biopharma company imploded overnight, a crypto firm went shopping, and a new HIV pill cleared its biggest regulatory hurdle — all before the weekend.
Top Stories
Affirm's blowout quarter shows buy-now-pay-later has real staying power even as consumers feel squeezed
Affirm posted 33% revenue growth and issued guidance well above what analysts expected, with CEO Max Levchin flagging that high gas prices are already pinching everyday shoppers — yet the company's loan quality held firm and its borrowing costs fell meaningfully.
The combination of strong credit discipline alongside accelerating growth is the hardest thing to pull off in consumer lending, and Affirm just did both at once.
BioXcel's bankruptcy is a reminder that AI branding cannot substitute for a viable business
The company, which marketed itself as an AI-driven drug developer, filed for Chapter 11 protection Thursday, wiping out nearly all of its shareholders' value in a single session.
The collapse is a pointed warning that the AI label attached to biotech firms over the past few years obscured real financial fragility that the market is now being forced to reckon with.
Cytokinetics proved its drug works — the market's sell-off reveals how high expectations had already climbed
The company reported that its heart drug aficamten meaningfully improved symptoms in patients with a genetic heart condition that currently has no approved treatments, a genuine clinical milestone.
The stock's sharp drop on undeniably good news tells you that the trial result was already priced in, and anything short of a surprise was always going to disappoint traders who had bid shares up in anticipation.
Also Today
- Gilead's new once-daily HIV pill wins FDA approval
- Walmart quietly settles federal opioid lawsuit with undisclosed terms
- Autodesk beats on revenue but cautious profit outlook spooks traders
Takeaway
Today's session was a study in the gap between narrative and reality — Affirm's numbers backed up the hype, Cytokinetics' science was real but the stock story was overextended, and BioXcel's AI story collapsed under the weight of a balance sheet that never matched the branding.
The week ahead turns on Affirm's analyst calls and whether Autodesk's management can convince the market its cautious profit guidance is conservatism rather than a warning sign.
